Fate Therapeutics, Inc. (FATE) Receives Outperform Rating from Leerink Swann
Fate Therapeutics, Inc. (NASDAQ:FATE)‘s stock had its “outperform” rating reiterated by stock analysts at Leerink Swann in a research note issued on Friday, Marketbeat.com reports. They currently have a $7.00 price target on the biopharmaceutical company’s stock. Leerink Swann’s price objective would indicate a potential upside of 69.90% from the company’s previous close.
A number of other research firms also recently weighed in on FATE. Wedbush reissued an “outperform” rating and set a $7.00 target price on shares of Fate Therapeutics in a research report on Tuesday, May 16th. Zacks Investment Research downgraded Fate Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday. Finally, ValuEngine raised Fate Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, August 29th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $6.42.
Shares of Fate Therapeutics (NASDAQ FATE) traded down 1.67% during mid-day trading on Friday, reaching $4.12. The company’s stock had a trading volume of 291,230 shares. The stock’s market capitalization is $170.63 million. The company has a 50 day moving average price of $3.14 and a 200 day moving average price of $3.74. Fate Therapeutics has a 12 month low of $1.80 and a 12 month high of $5.68.
Fate Therapeutics (NASDAQ:FATE) last released its earnings results on Monday, August 14th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.01. Fate Therapeutics had a negative return on equity of 67.01% and a negative net margin of 887.68%. The business had revenue of $1.03 million for the quarter, compared to the consensus estimate of $1.02 million. On average, equities research analysts anticipate that Fate Therapeutics will post ($0.96) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Fate Therapeutics, Inc. (FATE) Receives Outperform Rating from Leerink Swann” was reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/09/08/fate-therapeutics-inc-fate-receives-outperform-rating-from-leerink-swann.html.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. EcoR1 Capital LLC bought a new position in Fate Therapeutics during the first quarter worth about $11,543,000. Vanguard Group Inc. lifted its stake in Fate Therapeutics by 9.4% during the second quarter. Vanguard Group Inc. now owns 1,264,281 shares of the biopharmaceutical company’s stock worth $4,096,000 after purchasing an additional 108,602 shares during the period. Morgan Stanley lifted its stake in Fate Therapeutics by 9.8% during the first quarter. Morgan Stanley now owns 611,646 shares of the biopharmaceutical company’s stock worth $2,783,000 after purchasing an additional 54,615 shares during the period. State Street Corp bought a new position in Fate Therapeutics during the second quarter worth about $1,437,000. Finally, Northern Trust Corp lifted its stake in Fate Therapeutics by 968.7% during the second quarter. Northern Trust Corp now owns 368,208 shares of the biopharmaceutical company’s stock worth $1,193,000 after purchasing an additional 333,753 shares during the period. Hedge funds and other institutional investors own 64.27% of the company’s stock.
Fate Therapeutics Company Profile
Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.
Receive News & Ratings for Fate Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.